Rotavirus Infections
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
MAXVAX BiotechnologyChina - Chengdu
1 program1
Mid dose Recombinant Trivalent Subunit Rotavirus VaccinePhase 2Vaccine1 trial
Active Trials
M&
Merck & Co.RAHWAY, NJ
1 programROTATEQ™ Post-Marketing Surveillance in the PhilippinesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MAXVAX BiotechnologyMid dose Recombinant Trivalent Subunit Rotavirus Vaccine
Merck & Co.ROTATEQ™ Post-Marketing Surveillance in the Philippines
Clinical Trials (2)
Total enrollment: 915 patients across 2 trials
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
Start: Jan 2023Est. completion: Dec 2024
Phase 2Active Not Recruiting
ROTATEQ™ Post-Marketing Surveillance in the Philippines
Start: Oct 2007Est. completion: Sep 2010915 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space